Category: 3. Business

  • Chang Y, Cesarman E, Pessin MS, Lee F, Culpepper J, Knowles DM, et al. Identification of herpesvirus-like DNA sequences in AIDS-associated kaposi’s sarcoma. Science. 1994;266:1865–9. https://doi.org/10.1126/science.7997879.

    Google Scholar 

  • Cesarman E, Damania B, Krown SE, Martin J, Bower M, Whitby D. Kaposi sarcoma. Nat Rev Dis Primers. 2019;5:9. https://doi.org/10.1038/s41572-019-0060-9.

    Google Scholar 

  • Vischer HF, Siderius M, Leurs R, Smit MJ. Herpesvirus-encoded gpcrs: neglected players in inflammatory and proliferative diseases? Nat Rev Drug Discov. 2014;13:123–39. https://doi.org/10.1038/nrd4189.

    Google Scholar 

  • De Groof TWM, Elder EG, Siderius M, Heukers R, Sinclair JH, Smit MJ. Viral G protein–coupled receptors: attractive targets for herpesvirus-associated diseases. Pharmacol Rev. 2021;73:828–46. https://doi.org/10.1124/pharmrev.120.000186.

    Google Scholar 

  • Tsutsumi N, Kildedal DF, Hansen OK, Kong Q, Schols D, Van Loy T, et al. Insight into structural properties of viral G protein-coupled receptors and their role in the viral infection: IUPHAR Review 41. Br J Pharmacol. 2025;182:26–51. https://doi.org/10.1111/bph.17379.

    Google Scholar 

  • Syrovatkina V, Alegre KO, Dey R, Huang X-Y. Regulation, signaling, and physiological functions of G-proteins. J Mol Biol. 2016;428:3850–68. https://doi.org/10.1016/j.jmb.2016.08.002.

    Google Scholar 

  • Gurevich VV, Gurevich EV. GPCR signaling regulation: the role of GRKs and arrestins. Front Pharmacol. 2019;10:125. https://doi.org/10.3389/fphar.2019.00125.

    Google Scholar 

  • Nagarsheth N, Wicha MS, Zou W. Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy. Nat Rev Immunol. 2017;17:559–72. https://doi.org/10.1038/nri.2017.49.

    Google Scholar 

  • Kohli K, Pillarisetty VG, Kim TS. Key chemokines direct migration of immune cells in solid tumors. Cancer Gene Ther. 2022;29:10–21. https://doi.org/10.1038/s41417-021-00303-x.

    Google Scholar 

  • de Munnik SM, Smit MJ, Leurs R, Vischer HF. Modulation of cellular signaling by herpesvirus-encoded G protein-coupled receptors. Front Pharmacol. 2015. https://doi.org/10.3389/fphar.2015.00040.

    Google Scholar 

  • Lyngaa R, Nørregaard K, Kristensen M, Kubale V, Rosenkilde MM, Kledal TN. Cell transformation mediated by the Epstein-Barr virus G protein-coupled receptor BILF1 is dependent on constitutive signaling. Oncogene. 2010;29:4388–98. https://doi.org/10.1038/onc.2010.173.

    Google Scholar 

  • Maussang D, Verzijl D, Van Walsum M, Leurs R, Holl J, Pleskoff O, et al. Human cytomegalovirus-encoded chemokine receptor US28 promotes tumorigenesis. Proc Natl Acad Sci USA. 2006;103:13068–73. https://doi.org/10.1073/pnas.0604433103.

    Google Scholar 

  • Bais C, Santomasso B, Coso O, Arvanitakis L. G-protein-coupled receptor of kaposi’s sarcoma-associated herpesvirus is a viral oncogene and angiogenesis activator. Nature. 1998;391:86–9. https://doi.org/10.1038/34193.

    Google Scholar 

  • Yang T-Y, Chen S-C, Leach MW, Manfra D, Homey B, Wiekowski M, et al. Transgenic Expression of the Chemokine Receptor Encoded by Human Herpesvirus 8 Induces an Angioproliferative Disease Resembling Kaposi’s Sarcoma. J Exp Med. 2000;191:445–54. https://doi.org/10.1084/jem.191.3.445.

    Google Scholar 

  • Holst PJ, Rosenkilde MM, Manfra D, Chen SC, Wiekowski MT, Holst B, et al. Tumorigenesis induced by the HHV8-encoded chemokine receptor requires ligand modulation of high constitutive activity. J Clin Invest. 2001;108:1789–96. https://doi.org/10.1172/JCI13622.

    Google Scholar 

  • Jensen KK, Manfra DJ, Grisotto MG, Martin AP, Vassileva G, Kelley K, et al. The Human Herpes Virus 8-Encoded Chemokine Receptor Is Required for Angioproliferation in a Murine Model of Kaposi’s Sarcoma. J Immunol. 2005;174:3686–94. https://doi.org/10.4049/jimmunol.174.6.3686.

    Google Scholar 

  • Cesarman E, Nador RG, Bai F, Bohenzky RA, Russo JJ, Moore PS, et al. Kaposi’s sarcoma-associated herpesvirus contains G protein-coupled receptor and cyclin D homologs which are expressed in Kaposi’s sarcoma and malignant lymphoma. J Virol. 1996;70:8218–23. https://doi.org/10.1128/jvi.70.11.8218-8223.1996.

    Google Scholar 

  • Chiou C-J, Poole LJ, Kim PS, Ciufo DM, Cannon JS, Ap Rhys CM, et al. Patterns of gene expression and a transactivation function exhibited by the vGCR (ORF74) chemokine receptor protein of Kaposi’s sarcoma-associated herpesvirus. J Virol. 2002;76:3421–39. https://doi.org/10.1128/JVI.76.7.3421-3439.2002.

    Google Scholar 

  • Cannon M, Philpott NJ, Cesarman E. The kaposi’s Sarcoma-Associated herpesvirus G Protein-Coupled receptor has broad signaling effects in primary effusion lymphoma cells. J Virol. 2003;77:57–67. https://doi.org/10.1128/JVI.77.1.57-67.2003.

    Google Scholar 

  • Cannon ML, Cesarman E. The KSHV G protein-coupled receptor signals via multiple pathways to induce transcription factor activation in primary effusion lymphoma cells. Oncogene. 2004;23:514–23. https://doi.org/10.1038/sj.onc.1207021.

    Google Scholar 

  • Montaner S, Sodhi A, Servitja J-M, Ramsdell AK, Barac A, Sawai ET, et al. The small GTPase Rac1 links the Kaposi sarcoma–associated herpesvirus vGPCR to cytokine secretion and paracrine neoplasia. Blood. 2004;104:2903–11. https://doi.org/10.1182/blood-2003-12-4436.

    Google Scholar 

  • Shepard LW, Yang M, Xie P, Browning DD, Voyno-Yasenetskaya T, Kozasa T, et al. Constitutive activation of NF-κB and secretion of interleukin-8 induced by the G protein-coupled receptor of Kaposi’s sarcoma-associated herpesvirus involve Gα13 and RhoA. J Biol Chem. 2001;276:45979–87. https://doi.org/10.1074/jbc.M104783200.

    Google Scholar 

  • Boon K, Vanalken N, Szpakowska M, Chevigné A, Schols D, Van Loy T. Systematic assessment of chemokine ligand bias at the human chemokine receptor CXCR2 indicates G protein bias over β-arrestin recruitment and receptor internalization. Cell Commun Signal. 2024;22:43. https://doi.org/10.1186/s12964-023-01460-2.

    Google Scholar 

  • Arvanitakis L, Geras-Raaka E, Varma A, Gershengorn MC, Cesarman E. Human herpesvirus KSHV encodes a constitutively active G-protein-coupled receptor linked to cell proliferation. Nature. 1997;385:347–50. https://doi.org/10.1038/385347a0.

    Google Scholar 

  • Geras-Raaka E, Varma A, Ho H, Clark-Lewis I, Gershengorn MC. Human Interferon-γ–inducible protein 10 (IP-10) inhibits constitutive signaling of kaposi’s Sarcoma–associated herpesvirus G protein–coupled receptor. J Exp Med. 1998;188:405–8. https://doi.org/10.1084/jem.188.2.405.

    Google Scholar 

  • Gershengorn MC, Geras-Raaka E, Varma A, Clark-Lewis I. Chemokines activate kaposi’s sarcoma-associated herpesvirus G protein-coupled receptor in mammalian cells in culture. J Clin Invest. 1998;102:1469–72. https://doi.org/10.1172/JCI4461.

    Google Scholar 

  • Geras-Raaka E, Varma A, Clark-Lewis I, Gershengorn MC. Kaposi’s sarcoma-associated herpesvirus (KSHV) chemokine vMIP-II and human SDF-1α inhibit signaling by KSHV G protein-coupled receptor. Biochem Biophys Res Commun. 1998;253:725–7. https://doi.org/10.1006/bbrc.1998.9557.

    Google Scholar 

  • Rosenkilde MM, Kledal TN, Bräuner-Osborne H, Schwartz TW. Agonists and inverse agonists for the herpesvirus 8-encoded constitutively active seven-transmembrane oncogene product, ORF-74. J Biol Chem. 1999;274:956–61. https://doi.org/10.1074/jbc.274.2.956.

    Google Scholar 

  • Ho HH, Du D, Gershengorn MC. The N terminus of Kaposi’s sarcoma-associated herpesvirus G protein-coupled receptor is necessary for high affinity chemokine binding but not for constitutive activity. J Biol Chem. 1999;274:31327–32. https://doi.org/10.1074/jbc.274.44.31327.

    Google Scholar 

  • Rosenkilde MM, Schwartz TW. Potency of ligands correlates with affinity measured against agonist and inverse agonists but not against neutral ligand in constitutively active chemokine receptor. Mol Pharmacol. 2000;57:602–9. https://doi.org/10.1124/mol.57.3.602.

    Google Scholar 

  • Schwarz M, Murphy PM. Kaposi’s sarcoma-associated herpesvirus G protein-coupled receptor constitutively activates NF-κB and induces proinflammatory cytokine and chemokine production via a C-terminal signaling determinant. J Immunol. 2001;167:505–13. https://doi.org/10.4049/jimmunol.167.1.505.

    Google Scholar 

  • Pati S, Cavrois M, Guo HG, Foulke JSJ, Kim J, Feldman RA, et al. Activation of NF-kappaB by the human herpesvirus 8 chemokine receptor ORF74: evidence for a paracrine model of kaposi’s sarcoma pathogenesis. J Virol United States. 2001;75:8660–73. https://doi.org/10.1128/jvi.75.18.8660-8673.2001.

    Google Scholar 

  • Hensbergen PJ, Verzijl D, Balog CIA, Dijkman R, van der Schors RC, van der Raaij-Helmer EMH, et al. Furin is a chemokine-modifying enzyme: in vitro and in vivo processing of CXCL10 generates a C-terminally truncated chemokine retaining full activity. J Biol Chem United States. 2004;279:13402–11. https://doi.org/10.1074/jbc.M312814200.

    Google Scholar 

  • de Munnik SM, van der Lee R, Velders DM, van Offenbeek J, de Smits- Vries L, Leurs R, et al. The viral G protein-coupled receptor ORF74 unmasks phospholipase C signaling of the receptor tyrosine kinase IGF-1R. Cell Signal. 2016;28:595–605. https://doi.org/10.1016/j.cellsig.2016.02.017.

    Google Scholar 

  • Cornaby C, Tanner A, Stutz EW, Poole BD, Berges BK. Piracy on the molecular level: human herpesviruses manipulate cellular chemotaxis. J Gen Virol Microbiol Soc. 2016;97:543–60. https://doi.org/10.1099/jgv.0.000370.

    Google Scholar 

  • Couty J-P, Lupu-Meiri M, Oron Y, Gershengorn MC. Kaposi’s sarcoma-associated herpesvirus-G protein-coupled receptor-expressing endothelial cells exhibit reduced migration and stimulated chemotaxis by chemokine inverse agonists. J Pharmacol Exp Ther. 2009;329:1142–7. https://doi.org/10.1124/jpet.108.147686.

    Google Scholar 

  • Liu L, Doijen J, D’huys T, Verhaegen Y, Dehaen W, De Jonghe S, et al. Biological characterization of ligands targeting the human CC chemokine receptor 8 (CCR8) reveals the biased signaling properties of small molecule agonists. Biochem Pharmacol. 2021;188:114565. https://doi.org/10.1016/j.bcp.2021.114565.

    Google Scholar 

  • Schoofs G, Van Hout A, D’huys T, Schols D, Van Loy T. A flow Cytometry-based assay to identify compounds that disrupt binding of Fluorescently-labeled CXC chemokine ligand 12 to CXC chemokine receptor 4. JoVE. 2018;57271. https://doi.org/10.3791/57271.

  • Claes S, D’huys T, Van Hout A, Schols D, Van Loy T. A kinetic Fluorescence-based Ca2+ mobilization assay to identify G Protein-coupled receptor Agonists, Antagonists, and allosteric modulators. JoVE. 2018;56780. https://doi.org/10.3791/56780.

  • Dixon AS, Schwinn MK, Hall MP, Zimmerman K, Otto P, Lubben TH, et al. Nanoluc complementation reporter optimized for accurate measurement of protein interactions in cells. ACS Chem Biol. 2016;11:400–8. https://doi.org/10.1021/acschembio.5b00753.

    Google Scholar 

  • Liu C, Sandford G, Fei G, Nicholas J. Ga protein selectivity determinant specified by a viral chemokine receptor-conserved region in the C tail of the human herpesvirus 8 G protein-coupled receptor. J Virol. 2004. https://doi.org/10.1128/jvi.78.5.2460-2471.2004.

    Google Scholar 

  • de Munnik SM, Kooistra AJ, van Offenbeek J, Nijmeijer S, de Graaf C, Smit MJ, et al. The viral G protein-coupled receptor ORF74 hijacks β-arrestins for endocytic trafficking in response to human chemokines. PLoS One. 2015;10:e0124486. https://doi.org/10.1371/journal.pone.0124486.

    Google Scholar 

  • Bogacka J, Pawlik K, Ciapała K, Ciechanowska A, Mika J. CC chemokine receptor 4 (CCR4) as a possible new target for therapy. Int J Mol Sci. 2022;23:15638. https://doi.org/10.3390/ijms232415638.

    Google Scholar 

  • Liu A, Liu Y, Llinàs Del Torrent Masachs C, Zhang W, Pardo L, Ye RD. Structural insights into KSHV-GPCR constitutive activation and CXCL1 chemokine recognition. Proc Natl Acad Sci U S A. 2024;121:e2403217121. https://doi.org/10.1073/pnas.2403217121.

    Google Scholar 

  • Park JB, Sahoo B, Sahoo AR, Kim D, Seo HD, Bowman J, et al. Structural basis for ligand promiscuity and high signaling activity of kaposi’s Sarcoma-associated Herpesvirus-encoded GPCR. Nat Commun. 2025;16:8403. https://doi.org/10.1038/s41467-025-63457-4.

    Google Scholar 

  • Rosenkilde MM, Kledal TN, Holst PJ, Schwartz TW. Selective elimination of high constitutive activity or chemokine binding in the human herpesvirus 8 encoded seven transmembrane oncogene ORF74. J Biol Chem. 2000;275:26309–15. https://doi.org/10.1074/jbc.M003800200.

    Google Scholar 

  • Feng H, Sun Z, Farzan MR, Feng P. Sulfotyrosines of the kaposi’s Sarcoma-Associated herpesvirus G Protein-Coupled receptor promote tumorigenesis through autocrine activation. J Virol. 2010;84:3351–61. https://doi.org/10.1128/JVI.01939-09.

    Google Scholar 

  • Zhang R, Xie X. Tools for GPCR drug discovery. Acta Pharmacol Sin. 2012;33:372–84. https://doi.org/10.1038/aps.2011.173.

    Google Scholar 

  • Zhang J, He S, Wang Y, Brulois K, Lan K, Jung JU, et al. Herpesviral G protein-coupled receptors activate NFAT to induce tumor formation via inhibiting the SERCA calcium ATPase. PLoS Pathog. 2015;11:e1004768. https://doi.org/10.1371/journal.ppat.1004768.

    Google Scholar 

  • Machleidt T, Woodroofe CC, Schwinn MK, Méndez J, Robers MB, Zimmerman K, et al. NanoBRET—a novel BRET platform for the analysis of Protein–Protein interactions. ACS Chem Biol. 2015;10:1797–804. https://doi.org/10.1021/acschembio.5b00143.

    Google Scholar 

  • Ma X, Leurs R, Vischer HF. NanoLuc-Based Methods to Measure β-Arrestin2 Recruitment to G Protein-Coupled Receptors. New York, NY: Springer US; 2021. pp. 233–48. https://doi.org/10.1007/978-1-0716-1221-7_16. G Protein-Coupled Receptor Screening Assays [Internet].

  • Luo J, Li D, Wei D, Wang X, Wang L, Zeng X. RhoA and RhoC are involved in stromal cell-derived factor-1-induced cell migration by regulating F-actin redistribution and assembly. Mol Cell Biochem. 2017;436:13–21. https://doi.org/10.1007/s11010-017-3072-3.

    Google Scholar 

  • Michaelis UR. Mechanisms of endothelial cell migration. Cell Mol Life Sci. 2014;71:4131–48. https://doi.org/10.1007/s00018-014-1678-0.

    Google Scholar 

  • Couty J-P, Geras-Raaka E, Weksler BB, Gershengorn MC. Kaposi’s Sarcoma-associated Herpesvirus G Protein-coupled Receptor Signals through Multiple Pathways in Endothelial Cells. J Biol Chem. 2001;276:33805–11. https://doi.org/10.1074/jbc.m104631200.

    Google Scholar 

  • Smit MJ, Verzijl D, Casarosa P, Navis M, Timmerman H, Leurs R. Kaposi’s sarcoma-associated herpesvirus-encoded G protein-coupled receptor ORF74 constitutively activates p44/p42 MAPK and Akt via G(i) and phospholipase C-dependent signaling pathways. J Virol. 2002;76:1744–52. https://doi.org/10.1128/jvi.76.4.1744-1752.2002.

    Google Scholar 

  • Boldajipour B, Mahabaleshwar H, Kardash E, Reichman-Fried M, Blaser H, Minina S, et al. Control of chemokine-guided cell migration by ligand sequestration. Cell. 2008;132:463–73. https://doi.org/10.1016/j.cell.2007.12.034.

    Google Scholar 

  • Décaillot FM, Kazmi MA, Lin Y, Ray-Saha S, Sakmar TP, Sachdev P. CXCR7/CXCR4 heterodimer constitutively recruits β-arrestin to enhance cell migration. J Biol Chem. 2011;286:32188–97. https://doi.org/10.1074/jbc.M111.277038.

    Google Scholar 

  • Desnoyer A, Dupin N, Assoumou L, Carlotti A, Gaudin F, Deback C, et al. Expression pattern of the CXCL12/CXCR4-CXCR7 trio in Kaposi sarcoma skin lesions. Br J Dermatol. 2016;175:1251–62. https://doi.org/10.1111/bjd.14748.

    Google Scholar 

  • Kwon E-K, Min C-K, Kim Y, Lee J-W, Aigerim A, Schmidt S, et al. Constitutive activation of T cells by γ2-herpesviral GPCR through the interaction with cellular CXCR4. Biochimica et Biophysica Acta (BBA) – Molecular Cell Research. 2017;1864:1–11. https://doi.org/10.1016/j.bbamcr.2016.10.008.

    Google Scholar 

  • Nijmeijer S, Leurs R, Smit MJ, Vischer HF. The Epstein-Barr virus-encoded G protein-coupled receptor BILF1 hetero-oligomerizes with human CXCR4, scavenges Gαi proteins, and constitutively impairs CXCR4 functioning. J Biol Chem. 2010;285:29632–41. https://doi.org/10.1074/jbc.M110.115618.

    Google Scholar 

  • Gouwy M, Struyf S, Noppen S, Schutyser E, Springael J-Y, Parmentier M, et al. Synergy between coproduced CC and CXC chemokines in monocyte chemotaxis through Receptor-Mediated events. Mol Pharmacol. 2008;74:486–96. https://doi.org/10.1124/mol.108.045146.

    Google Scholar 

  • Lane BR, Liu J, Bock PJ, Schols D, Coffey MJ, Strieter RM, et al. Interleukin-8 and growth-regulated oncogene alpha mediate angiogenesis in Kaposi’s sarcoma. J Virol. 2002;76:11570–83. https://doi.org/10.1128/JVI.76.22.11570-11583.2002.

    Google Scholar 

  • Xu Y, Ganem D. Induction of chemokine production by latent kaposi’s sarcoma-associated herpesvirus infection of endothelial cells. J Gen Virol. 2007;88:46–50. https://doi.org/10.1099/vir.0.82375-0.

    Google Scholar 

  • Lee M, Lee J, Kang S, Wirth D, Yoo S, Park C. CXCL1 confers a survival advantage in Kaposi’s sarcoma-associated herpesvirus‐infected human endothelial cells through STAT3 phosphorylation. J Med Virol. 2023;95:jmv.28020. https://doi.org/10.1002/jmv.28020.

    Google Scholar 

  • Korbecki J, Bosiacki M, Szatkowska I, Kupnicka P, Chlubek D, Baranowska-Bosiacka I. The clinical significance and involvement in molecular cancer processes of chemokine CXCL1 in selected tumors. IJMS. 2024;25:4365. https://doi.org/10.3390/ijms25084365.

    Google Scholar 

  • Li X, Ohler ZW, Day A, Bassel L, Grosskopf A, Afsari B et al. Mapping herpesvirus-driven impacts on the cellular milieu and transcriptional profile of Kaposi sarcoma in patient-derived mouse models. BioRxiv. 2024. https://doi.org/10.1101/2024.09.27.615429. Cited 2025 Sep 9.

  • Knowlton ER, Rappocciolo G, Piazza P, Lepone LM, Nadgir SV, Bullotta A, et al. Human herpesvirus 8 induces polyfunctional B lymphocytes that drive Kaposi’s sarcoma. mBio. 2014;5:e01277-14. https://doi.org/10.1128/mBio.01277-14.

    Google Scholar 

  • Pontejo SM, Murphy PM, Pease JE. Chemokine subversion by human herpesviruses. J Innate Immun. 2018;10:465–78. https://doi.org/10.1159/000492161.

    Google Scholar 

  • Palande V, Roden RBS, Choi YB. Nano-luciferase complementation assay of human herpesvirus 8 chemo/cytokine-receptor interactions. Sci Rep. 2025;15:35365. https://doi.org/10.1038/s41598-025-19281-3.

    Google Scholar 

  • West J, Damania B. Upregulation of the TLR3 pathway by kaposi’s sarcoma-associated herpesvirus during primary infection. J Virol. 2008;82:5440–9. https://doi.org/10.1128/JVI.02590-07.

    Google Scholar 

  • Neumeyer S, Tagawa T. The Kaposi sarcoma herpesvirus control of monocytes, macrophages, and the tumour microenvironment. Virology. 2025;601:110286. https://doi.org/10.1016/j.virol.2024.110286.

    Google Scholar 

Continue Reading

  • ‘Superfluous consumerism’: adult Advent calendar trend alarms green groups | Christmas

    ‘Superfluous consumerism’: adult Advent calendar trend alarms green groups | Christmas

    The trend for Advent calendars aimed at adults is “superfluous consumerism” that adds to excessive and wasteful consumption, according to environmental groups.

    While once children excitedly opened a door each day to see what festive picture lay behind it, adults can now count down the days to Christmas with calendars containing everything from luxury beauty products to instant mashed potato.

    This year’s adult versions include beauty calendars such as the Nivea Women’s one at about £30 and one from Liberty priced at £275.

    But some have raised concerns over the packaging involved in providing 24 products to either be unwrapped or revealed each day, and the potential for unwanted items.

    Anna Diski, a plastics campaigner at Greenpeace UK, said: “Advent calendars like these probably contain two or three items you actually want, and 20 or so more you could do without. You don’t want that single-use plastic lingering in your bathroom cabinet, let alone in the natural environment.”

    Daniel Webb, the founder and director of the charity Everyday Plastic, said: “These luxury Advent calendars are a microcosm of a bigger problem, a system that keeps producing more and more stuff we don’t need and probably can’t afford.”

    The research firm Ipsos found seven in 10 Britons have a some point purchase an Advent calendar. While most bought chocolate ones (84%), beauty calendars are increasingly popular (15%), along with toy calendars (14%) and non-chocolate food versions (10%).

    The firm’s consumer intelligence platform, Ipsos Synthesio, has found online discussions around Advent calendars begin as early as September, driven by promotions by retailers and influencer-led unboxing videos.

    Webb said that encouraging people to shop for Christmas in the autumn was a decision “made by marketing departments, purely designed to drive overconsumption, not celebration”.

    He added: “I’m sure people find it fun and this isn’t about blaming anyone for wanting to celebrate – it’s about questioning why brands are choosing to fuel the waste crisis in this way. Real change means cutting plastic production and phasing out this kind of superfluous consumerism.”

    The beauty expert, journalist and author Sali Hughes said it was important to focus on asking “whether you would want at least five of the advent items if sold at full price”.

    She added: “If the answer is yes, then the whole calendar is probably worth the spend. If it’s no, then it’s a lot of money for the sake of novelty.

    “I also think it’s worthwhile imagining all the products in a pile, without the seductive packaging. If it consequently loses its allure, then you’re paying all that money for something pretty ephemeral that will, if its even been designed responsibly in the first place, just go into recycling after Christmas.”

    Samantha Dover, the insights director of beauty at the market analyst Mintel, said: “The adult Advent calendar trend isn’t going anywhere anytime soon, but the landscape in which these calendars sit is changing. In beauty, the high cost of many Advent calendars, even if they promise significant savings compared to buying individual products, means they are out of reach for many consumers.”

    Dover said the perceived savings mean they were still viewed as “good value for money”, adding: “It is likely that many consumers self-gift themselves calendars, and even split the cost with others and share products, as a result.” She said this could help reduce “waste often generated by Advent calendars”.

    Dr Christopher Carrick, the founder of bio-plastics manufacturer Lingin Industries, said government legislation was likely to have an impact on the calendars, which he described as “more packaging intensive, compared to the amount of actual product, than almost any other aspect of Christmas”.

    He said: “The extended producer responsibility which charges companies based on the amount of unsustainable packaging they put into the world is putting pressure on companies producing Advent calendars to reduce the amount of packaging.

    “This year, brands will have more responsibility over the costs associated with the waste generated by packaging, meaning designs and materials will need to be amended.”

    Continue Reading

  • X Introduces ‘About This Account’ Feature To Tackle Bots, Fake Profiles

    X Introduces ‘About This Account’ Feature To Tackle Bots, Fake Profiles

    To view your account details on either the X website or mobile app, you simply need to click on the “Joined” date displayed on your profile. This action opens a page that provides various pieces of information about your account, including the date you joined X, the location linked to your account, the number of times your username has been changed, along with the date of the last change, and how you accessed the platform, such as through the App Store or Google Play.

    Although users from various parts of the world have reported seeing the new feature appear on their own profiles, TechCrunch reported that it has not been able to view this account information on other users’ profiles. 

    This is likely because X is allowing account holders some time to review their displayed information for accuracy and make any desired changes to their settings before the feature is made available more widely.

    X offers users the option to choose whether their profile displays their specific country or just a broader geographical region. Initially, this choice was intended for users in countries where free speech protections are limited, but it appears that even users in the US can select between showing their country or their region or their continent. By default, the profile displays the country unless the user opts otherwise.

    Continue Reading

  • Navigating Shareholder Engagement and Shareholder Activism: Essentials and Best Practices

    Navigating Shareholder Engagement and Shareholder Activism: Essentials and Best Practices

    Engaging with shareholders and responding to shareholder activism continue to be top-of-mind for public companies. These situations present opportunities for management teams and boards of directors to work together to communicate the company’s strategy and reinforce the ways in which the company is positioned for lasting success. Our experience helping numerous clients engage with and respond to their shareholders has given us insight on the practices that stand out as the most effective.

    Shareholder Engagement

    A thoughtfully designed shareholder engagement program is a critical tool for public companies, including those companies who are newly public, who have multi-class capital structures, or both.

    What Is Shareholder Engagement and Why Is It Important?

    “Shareholder engagement” is the ongoing dialogue between a company and its shareholders. It involves targeted and thoughtful outreach, response, and disclosure with the goal of communicating the company’s value creation strategy and governance choices, learning investors’ perspectives and priorities, and building the company’s creditability with investors. Done right, it is a two-way dialogue between the company and its investors.

    From the investor perspective, shareholder engagement provides insight into information not captured in the company’s public filings, including the company’s position on emerging topics. It also gives an opportunity for investors to directly share their observations and preferences with boards and management teams.

    Shareholder engagement can provide an early warning of possible shareholder dissatisfaction, which could ripen into overt shareholder activism. In many ways, it is the proverbial “canary in the coal mine” for understanding investor concerns. When there is shareholder dissatisfaction, or when a company otherwise needs to solicit the support of shareholders, the foundation of trust and credibility built from multiple cycles of engagement can be invaluable.

    Who Should Engage with Shareholders?

    Shareholder engagement should be driven by the company’s management team. The functional lead is typically the company’s investor relations officer, who will usually participate in all shareholder engagement sessions to ensure consistency of messaging. A select group of the most senior executives (such as one or both of the Chief Executive Officer (CEO) and Chief Financial Officer (CFO)) typically participate in meetings with key shareholders, and potentially in all engagement meetings. Beyond this group, functional leads (such as the head of human resources or the head of diversity) can participate if the investor has expressed an interest in these topics. A small, well-coordinated team is best. Third-party advisors almost never participate in engagement sessions, as shareholders want to hear directly from the company and not from its advisors.

    Increasingly, shareholders are requesting meetings with board members—especially the board chair or lead independent director and the chair of the board’s compensation committee.

    Providing shareholders with access to board members is a strategic choice, and one that should be made only after reflection on the identity of the shareholder, the goals of the meeting, and a consideration of the right participants on behalf of the company (including as to which director is the best spokesperson). In all instances, board members should meet with shareholders only with the prior knowledge and approval of the board, only in close coordination with the management team, and only after thorough preparation.

    Which Shareholders Should We Engage With?

    There is no fixed rule on which shareholders a company should target for engagement. Many companies utilize rough metrics to size their engagement efforts, such as focusing on their top 25 institutional holders or trying to engage with the top 50 percent of their shareholder base. The right shareholders to engage will necessarily be company-specific and, sometimes, topic-specific; engagement will also evolve over time as the shareholder base changes. Overall, a reasonable goal is to offer to engage with a sufficiently meaningful number of shareholders so that the company gains the benefit of a diversity of shareholder perspectives, including in respect of a diversity of investing styles. To manage internal resources, it may be helpful to conduct outreach in phases (particularly if a company has not engaged historically) so that the number of engagement meetings in a short period is not overwhelming. Finally, shareholders beyond the target group also may approach the company to engage on matters of importance to them, and the company will need to consider its approach to engagement with these shareholders.

    The nature of the engagement may vary across shareholders. For example, many institutional investors funnel engagement through their “stewardship” or “governance” teams, with the portfolio manager not always participating in the meeting. Meetings with a governance team tend, not surprisingly, to be more focused on governance matters. In contrast, the portfolio manager may participate in engagement meetings with active managers. As such, these sessions may delve deeper into a company’s strategy and financials.

    At many companies, the rise of index investing has resulted in a concentration of voting power in the hands of a relatively small number of institutional investors. Index investors are more passive, long-term focused, and interested in better understanding a company’s long-term strategy. Companies ignore index investors at their peril, and regular efforts should be made to engage with the governance teams at these investors. More generally, institutional investors carefully track each company’s engagement efforts and may be less favorably inclined to support a company that only tries to engage in years when the company needs shareholder support for a non-routine voting matter.

    In 2025, BlackRock, Vanguard, and State Street—the largest index investors—split their governance teams to better align with how the assets are managed at each institution (active, passive, or sustainability). This could complicate engagement efforts in 2025 and 2026, with each pool of capital varying on a company-by-company basis and being managed by separate teams with different voting and engagement frameworks.

    It is often not a bad sign if a shareholder turns down an engagement offer. Shareholders receive a great deal of requests for engagement and must prioritize their time. A shareholder declining an engagement meeting typically means that the shareholder is satisfied with the company and does not feel that direct engagement is warranted at that time. Companies get credit with the shareholder for making the offer, even if the shareholder does not accept it.

    Should We Engage with Shareholders Who Are Known “Activists”?

    The answer is almost always yes. Activists are investors or prospective investors, and the best course is usually to treat them in the same way you treat similarly situated “friendly” investors. Engagement with an activist can provide valuable intelligence on the activist’s perspective and possible next steps. (See the “Shareholder Activism” section below for additional thoughts.)

    When Should We Engage with Shareholders?

    Shareholder engagement is an annual, year-round activity. The best time to meet with shareholders is typically from September to February. This period is often known as the proxy “offseason,” and is when investors typically have more timing flexibility, and thus may be more willing to accept an invitation for engagement. It also allows sufficient time for boards and management teams to incorporate shareholder feedback into decisions and disclosures for the next year.

    Newly public companies should aim to establish connections with shareholders early rather than waiting until the company has seasoned in the public markets. Engagement efforts during the first year after going public can yield substantial dividends in ensuing years, both in building institutional capability and in developing relationships.

    How Should We Conduct a Meeting with Shareholders?

    Shareholders should leave an engagement meeting with the belief that the company was open to their views and honestly wants to hear and understand their concerns.

    Shareholder engagement meetings are typically scheduled for 30 minutes to one hour. The company should prepare, and send to the shareholder in advance, an agenda that lays out the key topics for the meeting; this can keep the discussion on track. It can be helpful to have someone take notes for the company’s use during the meeting.

    The company’s representatives should conduct the meeting and drive the discussion. Shareholders want to engage directly with the decisionmakers, so top management or a board member should be the company’s primary speakers. Throughout the meeting, the company will want to show that its participants have a strong command of the issues facing the company. Although not mandatory, executives generally engage most in discussions related to their functional areas. For example, the CEO would concentrate on questions and discussion related to strategy and “big picture” items, the CFO would focus on financials, and the General Counsel would focus on governance. Throughout the meeting, it is important for the company’s participants to demonstrate competence, alignment, and engagement.

    Approach the meeting as a discussion and not a negotiation. This means listening actively and soliciting feedback, and not being dismissive, defensive, or confrontational. It is natural for there to be issues on which the company and the shareholder disagree, but the company’s focus in the meeting should not be on trying to change the shareholder’s mind. Rather, the goal is to clearly and unemotionally communicate the company’s position, reasoning, and value creation strategy while also building credibility with shareholders.

    How Do We Prepare for an Engagement Meeting?

    Preparation is key for any shareholder meeting. Major preparatory work typically involves:

    • Assembling the engagement team. The investor relations officer often quarterbacks the engagement effort, with contributions and assistance from individuals in the finance, corporate strategy, and legal functions.

    • Reviewing the shareholder’s voting policies and guidelines (which are typically publicly disclosed), and how the shareholder has voted at the company historically. Mutual funds, registered investment companies, and persons required to make filings on Form 13F are generally required to file a Form NP-X, which contains information on how the investor voted at each company. There are several third-party services that collate Form NP-X data into an easy-to-digest format. Also important is developing an understand of who the key decision makers are at each investor, how to contact those persons, and what authority they have to “override” the investor’s general governance policies.

    • Benchmarking how the company’s practices compare to the shareholder’s voting policies and guidelines, if publicly disclosed.

    • Understanding who from the shareholder will participate in the meeting. Be aware that the meeting may be dominated by individuals from the investor’s governance team, and these individuals may have limited knowledge about the company or its business. In that regard, presenting a brief, one- or two-minute primer on the company at the outset may be helpful to orient the conversation.

    • Preparing the right talking points to articulate the company’s value creation strategy and governance practices, and how those compare to the shareholder’s policies and areas of interest.

    • Understanding aggregate historical voting patterns at the company, such as a failed “say-on-pay” vote and the reasons behind it.

    • Understanding several years of recommendations proxy advisory firm recommendations at the company and how these recommendations impact the vote at prior shareholder meetings.

    • Deciding on a strategy for how to proactively address tough topics, such as a failed say-on-pay vote. Although it can be tempting to hope that shareholders will not ask challenging questions or inquire about topics that are awkward for the company to discuss, it is typically better to proactively raise these items. Doing so builds credibility with shareholders, as it does not seem like the company is trying to “hide the ball.” Addressing tough topics can also “open the door” for the investor to engage in the discussion, which may be helpful given the guidance from the U.S. Securities and Exchange Commission (SEC) (see next section, “What Are the Legal Requirements to Be Aware Of?”).

    • Developing sample questions and answers to anticipate and respond to shareholder questions. Providing clear, succinct answers—instead of non-answers—is the best approach.

    • Preparing appropriate written materials to distribute in advance of the meeting. This is typically a tailored version of the company’s normal investor presentation, with additional information (often from the proxy statement) added on topics such as governance and executive compensation.

    Many companies—particularly as they are building experience with shareholder engagement, or where top management or a board member are participating—hold a “dress rehearsal” in advance of the meeting. This can be an effective way to ensure messaging consistency, develop natural hand-offs between participants, and allocate who will cover which topics.

    What Are the Legal Requirements to Be Aware Of?

    All communications with shareholders need to be made in compliance with Regulation FD, and shareholder engagement meetings are no exception. Some investors may seek to test the bounds of the company’s Regulation FD compliance, and the company’s participants may need to, politely but firmly, prevent the conversation from straying beyond what the company has already publicly disclosed or is prepared to publicly disclose.

    A shareholder is under no obligation to keep confidential the discussion in an engagement meeting. As such, the company’s participants in an engagement meeting should not say anything that they would not want to see in a subsequent letter from the shareholder to the company’s shareholders or in a press release issued by the shareholder.

    Generally, written materials provided to shareholders in engagement meetings are not required to be filed with the SEC as soliciting material so long as they are used in meetings held prior to the company filing its preliminary or definitive proxy statement. (To meet the company’s Regulation FD obligation, it may be necessary to file these materials with the SEC or post them on the company’s website.) Once a proxy statement is on file, the practice is to file written materials with the SEC because they may be soliciting material; in addition, filing at this time allows for widespread distribution of these materials to other shareholders at a time when the company is soliciting proxies. It is typically not necessary to retrieve any written materials distributed in advance of or at an engagement meeting.

    In early 2025, the SEC staff revised its guidance on how engagement with companies may affect a beneficial owner’s active/passive status for purposes of filings on Schedule 13G and Schedule 13D. Previously, engagement on topics such as ESG, staggered boards, poison pills, or executive pay was not deemed to be inconsistent with an investor maintaining its status as a Schedule 13G filer. Under the revised guidance, generally, an investor who describes its views and how it may inform voting decisions, without more, can still use Schedule 13G.

    Although compliance with the beneficial ownership reporting rules is ultimately a matter for the shareholder, this new guidance resulted in some investors pausing their engagement meetings for a period. We believe that investors have adjusted to this new guidance. Anecdotally, we have heard that it has resulted in investors expressing greater preference for the company to take the lead in framing the conversation (see previous section, “How Should We Conduct a Meeting with Shareholders?”) for more discussion on how an agenda provided by the company can be helpful) and for more investors to be in a “listen-only” posture. Some investors have also started to read a scripted engagement disclaimer at the beginning of a meeting. Even if an investor reads this type of script, we do not recommend altering how the company approaches the meeting.

    What Should Be the Goals for Engagement?

    The most important objective of shareholder engagement is the exchange of perspectives between the company and its investors. We believe that engagement meetings work best when they are a two-way dialogue, even if the two sides are not in alignment on what the company should do.

    Beyond exchanging ideas, companies may have a variety of objectives for engagement, and these objectives can impact how a company approaches the meeting.

    • Some companies may be engaging as a matter of good corporate hygiene and may not have a goal beyond simply meeting with shareholders. In this case, the engagement may be on high-level topics that are not especially tailored to the shareholder, with the goal primarily to keep the lines of communication open.

    • Other companies may be engaging to try to build or repair a relationship. These discussions will likely have a more focused agenda than a general engagement meeting, with the goal of a frank exchange of perspectives.

    • Still other companies may be gathering shareholder input on one or more issues, such as investor perspectives on the company’s pay practices. The goal of these meetings is for the investor to do more of the talking by providing its perspective and rationale.

    What Should We Do After We Engage?

    Post-meeting follow-up is often overlooked. Companies should promptly satisfy any commitments (such as providing additional information) made during the meeting. One or more meetings of the company’s engagement working group to discuss the results of the engagement, either after key meetings or at the end of the engagement cycle, can be useful to share impressions, agree on takeaways, and plan for the future.

    We recommend that management teams be transparent with their boards of directors about the results of engagement efforts. This means providing the board with the unvarnished perspectives received, even if these perspectives are not universally flattering to the company, management, or the board. Sharing candid feedback allows the board to understand how investors see the company and consider whether change is warranted. It avoids a circumstance where the board is, in the future, surprised to learn of investor dissatisfaction. Especially in the shareholder activism context, this type of surprise can generate mistrust between the board and management team at precisely the time when trust between these two groups is critical.

    After gathering shareholder feedback and informing the board, the board and management team should review the feedback to determine if adjustments to the company’s strategy, governance, compensation practices, or other areas are necessary. If changes are determined to be warranted, the board and management team should establish a timeline and implementation approach, as well as the right way to communicate these changes to investors. Ultimately, gathering feedback is futile if the company is not going to use that feedback to inform its decision-making.

    What Are Other Best Practices?

    Shareholder engagement is good governance, and companies benefit from being transparent about their engagement efforts. Many companies disclose details on the number of shareholders contacted, the number of meetings held, the feedback received, and the actions taken in response to the feedback. Some companies even include “what we heard, what we did” charts and summaries in their proxy statements. These charts and summaries describe the nature of shareholder feedback received over the course of the year and detail how the company responded to that feedback. Even if this detailed disclosure is not included in the proxy statement, it can be helpful to organize the information in this manner for purposes of discussions with the board and its committees. This information requires careful recordkeeping and tracking of investor interactions—a job that often falls to the legal team if a company does not yet have a robust investor relations function.

    When reporting on shareholder feedback, do not ignore hard feedback. Although it is tempting to not publicly acknowledge areas where there is disagreement between the company and investors, it is— similar to addressing tough topics in the engagement meetings—often better to address these items head on and explain why the company made the choices that it did. For example, if shareholders are unsatisfied with the executive compensation program, use the engagement disclosure to explain the company’s view on why the program is appropriate. This shows that the company listened to—and understood—the feedback. Shareholders do not expect companies to meet every request, but they do expect to see that the company listened and has a defensible approach for its choices.

    Shareholder Activism

    Shareholder activism is a fact of life for public companies. Activism is its own asset class, with billions of dollars allocated to investors who pursue “activist” strategies. Shareholder engagement can be helpful in anticipating and understanding shareholder activism, but it cannot eliminate it.

    What Is Shareholder Activism?

    “Shareholder activism” occurs when shareholders use their ownership rights in a company to influence its board and management to make changes to the company’s policies, operations, or strategic direction. Broadly speaking, shareholder activism exists on a spectrum, with governance-focused activists (especially those who frequently utilize the SEC’s Rule 14a-8 process) on one end and financial activists (such as hedge funds) on the other end. Financial activists are the focus of the thoughts below.

    What Is the Current State of Shareholder Activism?

    Shareholder activism continues to be a significant challenge to a company’s policies and practices. Every company (even if it has significant friendly shareholders or a multi-class capital structure) is vulnerable to activism in some way, with that vulnerability increasing and decreasing depending on the company’s circumstances.

    A shareholder activist’s goal is to find a catalyst to increase a company’s stock price, which translates into money for the activist. A frequent catalyst is that the company should engage in a significant transaction, such as a sale of a division or the entire company. Beyond M&A, activists often focus on the company’s capital structure (including whether it is properly levered), its capital return practices (both as to dividends and share repurchases), operations and strategy (such as ways to improve profitability), and board composition (including whether there are directors who bring a “shareholder’s perspective” to the boardroom).

    Shareholder activists constantly evolve their tactics. Many activists are now willing to engage in multiyear campaigns, and some have shown a willingness to attack companies that fended off or settled with an activist in the recent past. We have also seen an increase in the number of activism campaigns that explicitly target the company’s CEO for replacement (including with the activist presenting its own CEO candidate) or question the board’s succession planning efforts. There also does not seem to be an “off-season” for activism, with activists showing a willingness to approach a company at any time of the year—even shortly after the shareholder meeting.

    The SEC’s universal proxy card rules provided activists with a fresh tactic to use against companies. These rules significantly increased the focus on the qualifications of each director. There is now a greater premium on explaining why each director serves on the board (for example, explaining the unique skills that each director brings). Further, universal proxy allows activists to “target” individual directors for replacement, which has resulted in greater vulnerability for directors with long tenures or who are older than 75, or who are “overboarded” or have attendance concerns. Although the universal proxy rules do not seem to have improved the overall success that activists have in proxy contests, they do seem have increased the number of settlements with activists. (See section below, “How Should We Think About Settlement with an Activist?”)

    How Should We Prepare for Shareholder Activism?

    The issues, tactics, challenges, and approaches in a shareholder activism situation will vary based on many factors, including the company, board dynamics, and the identity of the activist. That said, we believe that a thoughtful and well-executed shareholder engagement strategy is the best way to prepare for shareholder activism. As described above, the goal of shareholder engagement is to communicate the company’s value creation strategy and governance choices, learn investors’ perspectives and priorities, and build the company’s credibility with investors.

    Beyond engagement, the board of directors, in partnership with the management team, should frequently review the company’s strategy and operations (including the metrics used to make and evaluate decisions), approach to balancing growth and profitability, margin priorities, and other key business indicators. It is often said that boards should “think like an activist,” and this can be a useful construct for examining the business in a different way. For example, are there value creation strategies that the company could pursue? If so, should they be pursued, on what timeframe, and how should that be communicated to investors? If they should not be pursued, why not, and how should that be communicated? This work can help ensure alignment between the board and management team—and expose areas where additional analysis and discussion is needed to create that alignment.

    Regular board refreshment can be evidence of a healthy board dynamic and a willingness by the board to include new perspectives. Proactive board change can blunt an activist’s argument that the board is entrenched. To this end, maintaining a robust board succession plan and pipeline of director candidates can be very beneficial.

    Although governance rarely precipitates activism, it can serve as a wedge issue. Activists frequently claim that governance practices that they oppose—such as staggered boards—are evidence of a board that is entrenched and out-of-touch with shareholder desires. Regular reviews of the company’s governance policies and practices, along with frank conversations at the board level about whether they should evolve, are important preparatory work. Similarly, regular reviews of structural measures— such as advance notice bylaws to ensure that they are state-of-the-art—are good practice. At the same time, boards should be cautious about simply adopting “one-size-fits-all” governance practices (which are often advocated for by activists), as they practices may not be right for the company.

    Proactively assembling an activism response team—composed of key internal team members, outside counsel, a trusted financial advisor, a crisis communications firm, and a proxy solicitor—can save time and ensure that the company is able to respond rapidly to activism. This team should assemble and update a “break glass” response plan to be used if an activist targets the company. This plan is meaningfully bolstered if the team also takes the time to think through the key arguments that an activist could make in attacking the company and develop responses to those arguments. Although the final details of the company’s response will necessarily depend on the facts that exist at the time that the response is required, having draft materials can provide the company with a significant timing benefit. Activists frequently leverage their ability to strike quickly and with limited internal process to attempt to set and control the narrative. Advance work by the company can quicken its ability to respond.

    Interpersonal connections among the members of the response team can be valuable in responding to an activist challenge. To keep these connections strong and maintain preparedness, the response team should collectively conduct periodic “fire drills” and vulnerability assessments. Continuing to refine the company’s responses to a hypothetical activist challenge is important ongoing work for the response team, as is understanding the strategies and tactics of investors who have made activist approaches to other companies (especially those in the same industry).

    Companies should keep their eyes and ears open to investor perspectives communicated outside of formal engagement. For example, similar questions asked by different investors on earnings calls can be a sign of building investor consensus that should be understood. Robust investor surveillance efforts, including a stock watch service, can provide an early warning of an activist stock accumulation. Shareholders moving some of their holdings onto the transfer agent’s records—rather than holding beneficially through a bank or broker—can also be a telling sign that activism may be coming.

    Do Companies with Multi-Class Capital Structures Need to Think About Activism?

    Yes. Multi-class companies are often household names, and activism at these companies garners significant public attention. Even if the activist does not have a path to achieving its objectives, a campaign could generate significant publicity for the activist, in addition to positioning the activist for future fundraising efforts.

    How Should the Board Be Involved in Responding to Shareholder Activism?

    We think that the board and management team should see themselves as equal partners in addressing activism. This requires a frank and open dialogue between these groups about the company and its challenges and opportunities. As part of that, management should keep the board regularly updated about activism preparation and response. Ongoing director education—such as presentations by outside counsel on evolving activist tactics and the company’s vulnerabilities—can be helpful in demonstrating to the board that the management team has the company well-prepared for activism. The reputation and professional qualifications of directors are frequently attacked by activists. Activist attacks can be unnerving, and directors want to understand what the company will do in response. In addition, a unified board on key strategic issues is essential to successfully managing an activist attack, and it is hard to build and maintain that unity if directors do not feel that they have been kept informed. A lack of information provided to the board can further a frequent activist goal, which is to drive a wedge between management and the board by causing the board to question the company’s strategy management’s performance.

    Regular board updates are equally important when a company is actively engaging with an activist. The board should always have enough information to fulfill its oversight obligation, and we have found that directors are eager to understand how the company’s advisors and management team are approaching the situation. Some directors may also be called on to meet with the activist and will need to understand the entire state of play. Said differently, not involving the board in activism response has the potential to create a separation between management and the board at precisely the time when those two groups must be most aligned.

    Does the Board Need to Form a Special Committee to Respond to an Activist?

    Generally, a special committee is not necessary. The entire board has an inherent interest in the outcome, which means that there is typically no conflict of the type that would give rise to the need for a special committee. In addition, a special committee necessarily divides the board—at precisely the moment when an activist is seeking to do the same.

    How Should We Respond to An Activist?

    It is most common for activists to initially approach a company privately to express their concerns and plant the seeds for change. The company and the activist may disagree on many things, and engagement may seem futile—especially if the activist is strident in its criticisms. We think that it is a strategic mistake for a company not to engage robustly with an activist while the situation remains private, as keeping the situation private for as long as possible has significant advantages for the company. In addition, many investors expect companies to engage with activists with the goal of constructively working through their differences. But for the engagement to have a chance at being successful, the activist will want to know that 1) its views are being taken seriously and 2) the board is open to change, not asleep at the wheel, and not willfully blind to potential alternatives. This requires careful and frequent coordination between the board, the management team, and the company’s advisors to ensure that the right messages are being delivered in the right sequence.

    If private engagement fails, the activist may choose to make its criticisms public (or the activist may have chosen to go public from the outset). The company’s posture remains the same in a public attack: it should reinforce that the board is open-minded, takes shareholder feedback seriously, and is focused on building shareholder value. A public activism situation tends to be similar to a political campaign, with each side jockeying for shareholder support and to control the narrative. Companies do better in these situations when they take the high road and show that the board is sober, deliberative, and open to change, but also able to move quickly when circumstances warrant.

    Where Do Companies Go Wrong with Activists?

    Each activism situation is unique, and it is impossible to script how it will resolve or what direction it will go. That said, we think that companies have less success when:

    • the board and management team fail to speak with one voice (debate should be open and vigorous in the boardroom, but the board and management must be aligned publicly once a decision is made);

    • they are dismissive of the activist;

    • they implement a “scorched earth” defense, including by trying to be as aggressive as, or more aggressive than, the activist; and

    • they take things personally and allow decisions to be clouded by emotion.

    Engagement with an activist is asymmetric: shareholders will tolerate an activist doing and saying things about the company to a far greater extent than they will tolerate a company doing or saying similar things about the activist. In any activism response, the board should continually ask itself whether a proposed action will earn it more shareholder support than not taking the action and make decisions accordingly.

    How Should We Think About Settlement with an Activist?

    An activist’s ultimate leverage is to conduct a proxy contest to replace some or all of the members of the board. Directors who are nominated by an activist and elected by shareholders join a board with a mandate for change, and this can have a powerful impact on boardroom dynamics; this is true even at companies with classified boards where an activist can only elect a few directors each year. In addition, a proxy contest is disruptive to employees, customers, and other constituencies, will occupy a significant amount of board and management time and attention, and is costly.

    Given these factors, boards often look to resolve—or “settle”—an activism campaign before it evolves into a proxy contest through some type of negotiated compromise. These settlements can take many forms, but most often include some change to the composition of the board and the implementation of some aspects of the activist’s strategy (such as increased capital return or operational improvement initiatives). Companies can unilaterally adopt some or all of the activist’s requested changes without reaching a negotiated resolution with the activist; the objective of this strategy is to erode support for the activist among other shareholders by showing that the board is its own change agent and does not need outside pressure (or new directors chosen by the activist) to take bold action. Dialogue with other shareholders during the campaign can be helpful in understanding how they view the company and the activist’s critiques.

    There is no precise “right time” for when a company should pursue settlement. The leverage can change—favorably and unfavorably—as the campaign evolves. In some situations, the activist’s demands will be wrong for the company, and fighting the activist all the way to the shareholder meeting is the right decision. In others, a settlement can allow the company to return its full attention to execution. Overall, boards are well served when they are prepared to go the distance but flexible in their thinking about possible offramps to an activism campaign.

    Continue Reading

  • Exploring Valuation After Strong 21% Monthly Share Price Rally

    Exploring Valuation After Strong 21% Monthly Share Price Rally

    Astellas Pharma (TSE:4503) shares have caught some attention this month, returning 21% over that period. Investors may be wondering what is supporting this momentum and how the company’s recent fundamentals stack up.

    See our latest analysis for Astellas Pharma.

    After a steady climb, Astellas Pharma’s 30-day share price return of 21.04% and year-to-date gain of 28.65% have caught the market’s attention, suggesting renewed optimism. Over the past year, total shareholder return is 32.08%, reflecting both recent momentum and the company’s ability to deliver value to investors.

    If strong moves in healthcare have you curious about similar opportunities, now is an ideal time to explore See the full list for free.

    With shares rapidly gaining, the key question is whether Astellas Pharma is still undervalued based on its fundamentals or if the recent surge already reflects expectations of future growth. This may leave little room for upside.

    With Astellas Pharma’s last close of ¥1,964.5 sitting notably above the most widely followed fair value estimate of ¥1,774, there is an active debate over whether expectations are running ahead of fundamentals. The latest consensus narrative points to technology-driven momentum but also hints that immediate gains might not be assured.

    Bearish analysts note that while announcements regarding industry-wide CRM adoption are positive, they may not result in immediate incremental gains to near-term earnings. Concerns remain about execution risks during the transition to new digital platforms, especially given the complexity and scale of such projects at a global pharmaceutical company.

    Read the complete narrative.

    Curious what future financial assumptions could justify these premium valuations? One essential variable in the narrative is the projected transformation in profit margins and how those are achieved. Want to see what other key financial levers support this bold price target? Discover what is fueling this hot debate in the full narrative.

    Result: Fair Value of ¥1,774 (OVERVALUED)

    Have a read of the narrative in full and understand what’s behind the forecasts.

    However, risks such as increased global pricing pressure or setbacks for key drugs could challenge the current optimistic outlook on Astellas Pharma’s future growth.

    Find out about the key risks to this Astellas Pharma narrative.

    Looking at the same company through the lens of our SWS DCF model, the picture changes dramatically. According to this approach, Astellas Pharma actually appears to be trading 48.2% below its estimated fair value of ¥3,793.55. Could the market be overlooking long-term potential, or does the DCF make bold assumptions about the future?

    Look into how the SWS DCF model arrives at its fair value.

    4503 Discounted Cash Flow as at Nov 2025

    Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Astellas Pharma for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 918 undervalued stocks based on their cash flows. If you save a screener we even alert you when new companies match – so you never miss a potential opportunity.

    If these perspectives do not match your own thinking, dive into the numbers yourself. Craft your unique view in under three minutes. Do it your way

    A great starting point for your Astellas Pharma research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.

    Missing out on the next big winner is easier than you think. Get ahead by acting now and uncovering unique opportunities shaped by the world’s most powerful investing trends.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

    Companies discussed in this article include 4503.T.

    Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

    Continue Reading

  • Gauging Valuation After Q3 Beat, Raised Guidance, and Bullish Market Momentum

    Gauging Valuation After Q3 Beat, Raised Guidance, and Bullish Market Momentum

    West Pharmaceutical Services reported third-quarter results that outperformed expectations, with organic growth driving a 7.7% year-over-year increase in net sales. The company also raised its full-year guidance, supporting recent gains in the stock price.

    See our latest analysis for West Pharmaceutical Services.

    West Pharmaceutical’s recent 5.2% one-day share price jump came on the heels of strong quarterly results, a raised outlook, and a dose of positive macro sentiment around potential interest rate cuts. These catalysts have helped fuel a quick rebound for the stock, but shares are still down more than 17% year-to-date. Over the past three years, however, total shareholder return stands at a healthy 20.6%, which suggests long-term holders have still come out ahead even amid this year’s volatility and recent headline-driven gains.

    If you’re thinking about what’s next or looking to uncover similar stories, now could be the right moment to broaden your perspective and explore fast growing stocks with high insider ownership

    The recent surge in West Pharmaceutical Services’ share price has revived the debate among investors. Do the fundamentals and analyst optimism signal an undervalued opportunity, or is the market already pricing in coming growth?

    West Pharmaceutical Services’ last close at $271.07 sits well below the most widely followed narrative’s fair value estimate, which sees clear upside potential for the stock. The narrative frames this higher valuation around strategic growth bets and upcoming profitability improvements.

    The continued growth in GLP-1s, which made up about 7% of total revenues in the first quarter, and the company’s ability to capitalize on significant opportunities in this market could drive revenue and earnings growth. The introduction of an automated line for HVP delivery devices later in 2025 to early 2026 is expected to improve margins by driving operational efficiencies and scale, enhancing net margins.

    Read the complete narrative.

    Want to know the growth blueprint behind this high valuation? The narrative leans on bold future revenue and margin expansions that few competitors can realistically match. Get the details behind the aggressive projections that power this fair value. Uncover the pivotal turning points that analysts are betting on.

    Result: Fair Value of $350.77 (UNDERVALUED)

    Have a read of the narrative in full and understand what’s behind the forecasts.

    However, ongoing restructuring and any unexpected demand shifts for high-value components could quickly challenge these upbeat projections and change analysts’ confidence in the growth story.

    Find out about the key risks to this West Pharmaceutical Services narrative.

    Looking at West Pharmaceutical Services through the lens of price-to-earnings, the stock trades at 39.7x, which is well above both the industry average of 34.9x and the peer average of 29.9x. The fair ratio suggests a level of 26.5x, indicating the market may be pricing in a lot of optimism. Does this gap reflect real future potential, or are investors taking on more valuation risk than they realize?

    See what the numbers say about this price — find out in our valuation breakdown.

    NYSE:WST PE Ratio as at Nov 2025

    If you have your own perspective or want to dig deeper into the numbers, you can shape a unique narrative in just a few minutes. Do it your way

    A good starting point is our analysis highlighting 2 key rewards investors are optimistic about regarding West Pharmaceutical Services.

    Great opportunities are just a click away. If you want to put your cash to work in high-potential areas, don’t wait for the market to pass you by. Seize the moment with these handpicked routes to smart investing:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

    Companies discussed in this article include WST.

    Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

    Continue Reading

  • Genetic diversity and population structure of a core collection of Mediterranean durum wheat accessions using DArTseq markers | BMC Genomics

    Genetic diversity and population structure of a core collection of Mediterranean durum wheat accessions using DArTseq markers | BMC Genomics

  • De Vita P, Taranto F. Durum wheat (Triticum turgidum ssp. durum) breeding to Meet the challenge of climate change. In: Al-Khayri JM, Jain SM, Johnson DV, editors. Advances in plant breeding strategies: cereals: volume 5. Cham: Springer International Publishing; 2019. pp. 471–524.

    Google Scholar 

  • De Vita P, Taranto F, editors. Durum wheat breeding and genetics. Basel, Switzerland: MDPI – Multidisciplinary Digital Publishing Institute; 2020.

    Google Scholar 

  • Broccanello C, Bellin D, DalCorso G, Furini A, Taranto F. Genetic approaches to exploit landraces for improvement of Triticum turgidum ssp. Durum in the age of climate change. Front Plant Sci. 2023;14:1101271.

  • Grosse-Heilmann M, Cristiano E, Deidda R, Viola F. Durum wheat productivity today and tomorrow: a review of influencing factors and climate change effects. Resources, Environment and Sustainability. 2024;17:100170.

    Google Scholar 

  • Martínez-Moreno F, Solís I, Noguero D, Blanco A, Özberk İ, Nsarellah N, et al. Durum wheat in the mediterranean rim: historical evolution and genetic resources. Genet Resour Crop Evol. 2020;67:1415–36.

    Google Scholar 

  • Martínez-Moreno F, Ammar K, Solís I. Global changes in cultivated area and breeding activities of durum wheat from 1800 to date: a historical review. Agronomy. 2022;12:1135.

    Google Scholar 

  • Lopes MS, El-Basyoni I, Baenziger PS, Singh S, Royo C, Ozbek K, et al. Exploiting genetic diversity from landraces in wheat breeding for adaptation to climate change. J Exp Bot. 2015;66:3477–86.

    Google Scholar 

  • Xynias IN, Mylonas I, Korpetis EG, Ninou E, Tsaballa A, Avdikos ID, et al. Durum wheat breeding in the Mediterranean region: current status and future prospects. Agronomy. 2020;10:432.

    Google Scholar 

  • Tedone L, Ali SA, Verdini L, De Mastro G. Nitrogen management strategy for optimizing agronomic and environmental performance of rainfed durum wheat under mediterranean climate. J Clean Prod. 2018;172:2058–74.

    Google Scholar 

  • Sabella E, Aprile A, Negro C, Nicolì F, Nutricati E, Vergine M, et al. Impact of climate change on durum wheat yield. Agronomy. 2020;10:793.

    Google Scholar 

  • Rossini A, Ruggeri R, Belocchi A, Rossini F. Response of durum wheat cultivars to climate change in a mediterranean environment: trends of weather and crop variables at the turn of 21st century. J Agron Crop Sci. 2024;210:e12786.

    Google Scholar 

  • European Commission. (2024) Cereals market situation. Expert group for agricultural markets, subgroup arable crops and olive oil (E02730/2), Meeting Jan 29, Brussels, Point 3.1. https://ec.europa.eu/transparency/expert-groups-register/core/api/front/document/101943/download. Accessed 24 Feb 2025.

  • D’Odorico P, Emmel C, Revill A, Liebisch F, Eugster W, Buchmann N. Vertical patterns of photosynthesis and related leaf traits in two contrasting agricultural crops. Funct Plant Biol. 2018;46:213–27.

    Google Scholar 

  • Toreti A, Bavera D, Acosta NJ, Acquafresca L, Arias-Muñoz C, Avanzi F et al. Drought in the Mediterranean Region – January 2024. JRC Publications Repository. 2024. https://publications.jrc.ec.europa.eu/repository/handle/JRC137036. Accessed 25 Feb 2025.

  • Mazzucotelli E, Sciara G, Mastrangelo AM, Desiderio F, Xu SS, Faris J, et al. The global durum wheat panel (GDP): an international platform to identify and exchange beneficial alleles. Front Plant Sci. 2020;11:569905.

  • Maccaferri M, Harris NS, Twardziok SO, Pasam RK, Gundlach H, Spannagl M, et al. Durum wheat genome highlights past domestication signatures and future improvement targets. Nat Genet. 2019;51:885–95.

    Google Scholar 

  • Laribi M, Fredua-Agyeman R, Ben M, Sansaloni CP, Dreisigacker S, Gamba FM, et al. Genome-wide association analysis of Tan spot disease resistance in durum wheat accessions from Tunisia. Front Genet. 2023;14:1231027.

  • Hoisington D, Khairallah M, Gonzalez-de-Leon D. Laboratory protocols. 2nd ed. CIMMYT Applied Molecular Genetics Laboratory. CIMMYT: Texcoco, Mexico. 1994. Available at: http://repository.cimmyt.org/xmlui/bitstream/handle/10883/1333/91195.pdf (Accessed on April 20, 2015).

  • Gruber B, Unmack PJ, Berry OF, Georges A. Dartr: an R package to facilitate analysis of SNP data generated from reduced representation genome sequencing. Mol Ecol Resour. 2018;18:691–9.

    Google Scholar 

  • Liu K, Muse SV. PowerMarker: an integrated analysis environment for genetic marker analysis. Bioinformatics. 2005;21:2128–9.

    Google Scholar 

  • LiLin Y. Package CMplot. 7. 2018. https://github.com/YinLiLin/R-CMplot.

  • Jombart T. Adegenet: a R package for the multivariate analysis of genetic markers. Bioinformatics. 2008;24:1403–5.

    Google Scholar 

  • Goudet J, Jombart T, Goudet MJ. October. Package ‘hierfstat.’ Estimation and Tests of Hierarchical F-Statistics. 2015. Available online: https://cloudr-projectorg/ (Accessed on 13 2022).

  • Bradbury PJ, Zhang Z, Kroon DE, Casstevens TM, Ramdoss Y, Buckler ES. TASSEL: software for association mapping of complex traits in diverse samples. Bioinformatics. 2007;23:2633–5.

    Google Scholar 

  • Breseghello F, Sorrells ME. Association analysis as a strategy for improvement of quantitative traits in plants. Crop Sci. 2006;46:1323–30.

    Google Scholar 

  • Cleveland WS. Robust locally weighted regression and smoothing scatterplots. J Am Stat Assoc. 1979;74(368):829–36.

    Google Scholar 

  • Wickham H. Programming with ggplot2. In: ggplot2. Use R!. Cham: Springer; 2016. https://doi.org/10.1007/978-3-319-24277-4_12.

  • Weir BS, Cockerham CC. Estimating F-statistics for the analysis of population structure. Evolution. 1984;38:1358–70.

  • Woldeyohannes AB, Iohannes SD, Miculan M, Caproni L, Ahmed JS, de Sousa K, et al. Data-driven, participatory characterization of farmer varieties discloses teff breeding potential under current and future climates. Elife. 2022;11:e80009.

    Google Scholar 

  • Pritchard JK, Stephens M, Rosenberg NA, Donnelly P. Association mapping in structured populations. Am J Hum Genet. 2000;67:170–81.

    Google Scholar 

  • Evanno G, Regnaut S, Goudet J. Detecting the number of clusters of individuals using the software structure: a simulation study. Mol Ecol. 2005;14:2611–20.

    Google Scholar 

  • Earl DA, VonHoldt BM. Structure harvester: a website and program for visualizing STRUCTURE output and implementing the Evanno method. Conserv Genet Resour. 2012;4:359–61.

    Google Scholar 

  • Wang J, Zhang Z. GAPIT version 3: boosting power and accuracy for genomic association and prediction. Genomics Proteomics Bioinform. 2021;19:629–40.

    Google Scholar 

  • Hill WG, Weir BS. Variances and covariances of squared linkage disequilibria in finite populations. Theor Popul Biol. 1988;33:54–78.

    Google Scholar 

  • Kabbaj H, Sall AT, Al-Abdallat A, Geleta M, Amri A, Filali-Maltouf A, et al. Genetic diversity within a global panel of durum wheat (Triticum durum) landraces and modern germplasm reveals the history of alleles exchange. Front Plant Sci. 2017;8:1277.

  • Soriano JM, Villegas D, Aranzana MJ, del Moral LFG, Royo C. Genetic structure of modern durum wheat cultivars and mediterranean landraces matches with their agronomic performance. PLoS ONE. 2016;11:e0160983.

    Google Scholar 

  • Rufo R, Alvaro F, Royo C, Soriano JM. From landraces to improved cultivars: assessment of genetic diversity and population structure of mediterranean wheat using SNP markers. PLoS One. 2019;14:e0219867.

    Google Scholar 

  • Taranto F, D’Agostino N, Rodriguez M, Pavan S, Minervini AP, Pecchioni N, et al. Whole genome scan reveals molecular signatures of divergence and selection related to important traits in durum wheat germplasm. Front Genet. 2020;11:217.

  • Mahboubi M, Mehrabi R, Naji AM, Talebi R. Whole-genome diversity, population structure and linkage disequilibrium analysis of globally diverse wheat genotypes using genotyping-by-sequencing DArTseq platform. 3 Biotech. 2020;10:48.

    Google Scholar 

  • Ebrahimi P, Karami E, Etminan A, Talebi R, Mohammadi R. Genetic diversity and Genome-Wide association study for some agronomic traits in durum wheat (Triticum turgidum L.) using whole genome DArTseq markers. Plant Mol Biol Report. 2025:1–17.

  • Dukamo BH, Degu HD, Abitie AG, Asfaw BT. Genetic diversity analysis and population structure of selected Ethiopian durum wheat (T. turgidum subsp. durum) landraces using DArTseq markers. J Agric Food Res. 2024;18:101529.

    Google Scholar 

  • Fufa M, Gedebo A, Letta T, Lule D. Genetic diversity and population structure analysis in tetraploid wheat (Triticum turgidum spp) germplasm from Ethiopia based on DArTSeq markers. Genet Resour Crop Evol. 2024;71:2415–33.

    Google Scholar 

  • Baloch FS, Alsaleh A, Andeden EE, Hati̇Poğlu R, Nachit M, Özkan H. High levels of segregation distortion in the molecular linkage map of bread wheat representing the West Asia and North Africa region. Turk J Agric For. 2016;40:352–64.

    Google Scholar 

  • Baloch FS, Alsaleh A, Shahid MQ, Çiftçi V, de Miera LES, Aasim M, et al. A whole genome DArTseq and SNP analysis for genetic diversity assessment in durum wheat from central fertile crescent. PLoS ONE. 2017;12:e0167821.

    Google Scholar 

  • Alipour H, Bihamta MR, Mohammadi V, Peyghambari SA, Bai G, Zhang G. Genotyping-by-sequencing (GBS) revealed molecular genetic diversity of Iranian wheat landraces and cultivars. Front Plant Sci. 2017;8:1293.

    Google Scholar 

  • Sieber A-N, Longin CFH, Würschum T. Molecular characterization of winter durum wheat (Triticum durum) based on a genotyping-by-sequencing approach. Plant Genet Resour. 2017;15:36–44.

    Google Scholar 

  • Robbana C, Kehel Z, Ben Naceur M, Sansaloni C, Bassi F, Amri A. Genome-wide genetic diversity and population structure of Tunisian durum wheat landraces based on DArTseq technology. Int J Mol Sci. 2019;20:1352.

    Google Scholar 

  • Alemu A, Feyissa T, Letta T, Abeyo B. Genetic diversity and population structure analysis based on the high density SNP markers in Ethiopian durum wheat (Triticum turgidum ssp. durum). BMC Genet. 2020;21:18.

    Google Scholar 

  • Negisho K, Shibru S, Pillen K, Ordon F, Wehner G. Genetic diversity of Ethiopian durum wheat landraces. PLoS One. 2021;16:e0247016.

    Google Scholar 

  • Mulugeta B, Ortiz R, Geleta M, Hailesilassie T, Hammenhag C, Hailu F, et al. Harnessing genome-wide genetic diversity, population structure and linkage disequilibrium in Ethiopian durum wheat gene pool. Front Plant Sci. 2023;14:1192356.

  • Zohary D, Feldman M. Hybridization between amphidiploids and the evolution of polyploids in the wheat (Aegilops-Triticum) group. Evolution. 1962;16:44–61.

  • Maccaferri M, Sanguineti MC, Donini P, Tuberosa R. Microsatellite analysis reveals a progressive widening of the genetic basis in the elite durum wheat germplasm. Theor Appl Genet. 2003;107:783–97.

    Google Scholar 

  • Devos KM, Dubcovsky J, Dvořák J, Chinoy CN, Gale MD. Structural evolution of wheat chromosomes 4A, 5A, and 7B and its impact on recombination. Theor Appl Genet. 1995;91:282–8.

    Google Scholar 

  • Pascual L, Ruiz M, López-Fernández M, Pérez-Peña H, Benavente E, Vázquez JF, et al. Genomic analysis of Spanish wheat landraces reveals their variability and potential for breeding. BMC Genomics. 2020;21(1):122.

    Google Scholar 

  • Tyrka M, Mokrzycka M, Bakera B, Tyrka D, Szeliga M, Stojałowski S, et al. Evaluation of genetic structure in European wheat cultivars and advanced breeding lines using high-density genotyping-by-sequencing approach. BMC Genomics. 2021;22:81.

    Google Scholar 

  • Yang N, Ovenden B, Baxter B, McDonald MC, Solomon PS, Milgate A. Multi-stage resistance to zymoseptoria tritici revealed by GWAS in an Australian bread wheat (Triticum aestivum L.) diversity panel. Front Plant Sci. 2022;13:990915.

  • Akhunova AR, Matniyazov RT, Liang H, Akhunov ED. Homoeolog-specific transcriptional bias in allopolyploid wheat. BMC Genomics. 2010;11:505.

    Google Scholar 

  • Wang S, Wong D, Forrest K, Allen A, Chao S, Huang BE, et al. Characterization of polyploid wheat genomic diversity using a high-density 90 000 single nucleotide polymorphism array. Plant Biotechnol J. 2014;12:787–96.

    Google Scholar 

  • Ren J, Sun D, Chen L, You FM, Wang J, Peng Y, et al. Genetic diversity revealed by single nucleotide polymorphism markers in a worldwide germplasm collection of durum wheat. Int J Mol Sci. 2013;14:7061–88.

    Google Scholar 

  • Soriano JM, Sansaloni C, Ammar K, Royo C. Labelling selective sweeps used in durum wheat breeding from a diverse and structured panel of landraces and cultivars. Biology. 2021;10:258.

    Google Scholar 

  • Mengistu DK, Kidane YG, Fadda C, Pè ME. Genetic diversity in Ethiopian durum wheat (Triticum turgidum var durum) inferred from phenotypic variations. Plant Genetic Resour. 2018;16:39–49.

    Google Scholar 

  • Roncallo PF, Larsen AO, Achilli AL, Pierre CS, Gallo CA, Dreisigacker S, et al. Linkage disequilibrium patterns, population structure and diversity analysis in a worldwide durum wheat collection including Argentinian genotypes. BMC Genomics. 2021;22:233.

    Google Scholar 

  • Wang S, Xu S, Chao S, Sun Q, Liu S, Xia G. A genome-wide association study of highly heritable agronomic traits in durum wheat. Front Plant Sci. 2019;10:919.

    Google Scholar 

  • Roselló M, Royo C, Sanchez-Garcia M, Soriano JM. Genetic dissection of the seminal root system architecture in mediterranean durum wheat landraces by genome-wide association study. Agronomy. 2019;9:364.

    Google Scholar 

  • Fayaz F, Aghaee Sarbarzeh M, Talebi R, Azadi A. Genetic diversity and molecular characterization of Iranian durum wheat landraces (Triticum turgidum durum (Desf.) Husn.) using dart markers. Biochem Genet. 2019;57:98–116.

    Google Scholar 

  • Bassi FM, Brahmi H, Sabraoui A, Amri A, Nsarellah N, Nachit MM, et al. Genetic identification of loci for Hessian fly resistance in durum wheat. Mol Breed. 2019;39:24.

    Google Scholar 

  • Moragues M, Zarco-Hernández J, Moralejo MA, Royo C. Genetic diversity of glutenin protein subunits composition in Durum wheat landraces [Triticum turgidum ssp. turgidum Convar. durum (Desf.) MacKey] from the mediterranean basin. Genet Resour Crop Evol. 2006;53:993–1002.

    Google Scholar 

  • Moragues M, Moralejo M, Sorrells ME, Royo C. Dispersal of Durum wheat [Triticum Turgidum L. ssp. Turgidum convar. Durum (Desf.) MacKey] landraces across the mediterranean basin assessed by AFLPs and microsatellites. Genet Resour Crop Evol. 2007;54:1133–44.

    Google Scholar 

  • Feldman M. Origin of cultivated wheat. The world wheat book: a history of wheat breeding. 2001:3–53.

  • Serventi S, Sabban F, Pasta. The story of a universal food. Columbia University Press; 2002.

  • Mackey J. Wheat: its concept, evolution and taxonomy In: Royo C, Nachit MM, Di Fonzo N, Araus JL, Pfeiffer WH, Slafer GA, editors. 2005:35–94.

  • Abdelkader B. The history of wheat breeding in Algeria. In: Proceedings of the International Symposium on Genetics and Breeding of Durum Wheat (Options Méditerranéennes: Série, A. Séminaires Méditerranéens). 2014. p. 363–70.

  • Bozzini A. Origin, distribution, and production of durum wheat in the world. 1988. p. 1–14.

  • Moragues M, del Moral LFG, Moralejo M, Royo C. Yield formation strategies of durum wheat landraces with distinct pattern of dispersal within the Mediterranean basin I: yield components. Field Crops Res. 2006;95:194–205.

    Google Scholar 

  • Kottek M, Grieser J, Beck C, Rudolf B, Rubel F. World map of the Köppen-Geiger climate classification updated. Meteorol Z. 2006:15;259–63.

  • Ruiz M, Giraldo P, Royo C, Villegas D, Aranzana MJ, Carrillo JM. Diversity and genetic structure of a collection of Spanish durum wheat landraces. Crop Sci. 2012;52:2262–75.

    Google Scholar 

  • Oliveira HR, Campana MG, Jones H, Hunt HV, Leigh F, Redhouse DI, et al. Tetraploid wheat landraces in the mediterranean basin: taxonomy, evolution and genetic diversity. PLoS One. 2012;7:e37063.

    Google Scholar 

  • Balfourier F, Bouchet S, Robert S, De Oliveira R, Rimbert H, Kitt J, et al. Worldwide phylogeography and history of wheat genetic diversity. Sci Adv. 2019;5:eaav0536.

    Google Scholar 

  • Azeez MA, Adubi AO, Durodola FA. Landraces and crop genetic improvement. In: Grillo O, editor. Rediscovery of Landraces as a Resource for the Future. London: InTech; 2018.

  • Pecetti L, Annicchiarico P, Damania AB. Biodiversity in a germplasm collection of durum wheat. Euphytica. 1992;60:229–38.

    Google Scholar 

  • Slim A, Piarulli L, Chennaoui Kourda H, Rouaissi M, Robbana C, Chaabane R, et al. Genetic structure analysis of a collection of Tunisian durum wheat germplasm. Int J Mol Sci. 2019;20:3362.

    Google Scholar 

  • Laidò G, Mangini G, Taranto F, Gadaleta A, Blanco A, Cattivelli L, et al. Genetic diversity and population structure of tetraploid wheats (Triticum turgidum L.) estimated by SSR, dart and pedigree data. PLoS One. 2013;8:e67280.

    Google Scholar 

  • Continue Reading

  • A Fed rate cut next month seemed doubtful. Here’s why it’s now likely to happen.

    A Fed rate cut next month seemed doubtful. Here’s why it’s now likely to happen.

    By Greg Robb

    Despite dramatic differences among Fed officials, opinions are coalescing behind a third interest-rate cut in succession

    Federal Reserve Chair Jerome Powell speaks at a press conference in October.

    Over the past month, there have been sharp public disagreements among Federal Reserve officials about the likely path of the economy and the appropriate level of interest rates. These public debates led economists and market participants to doubt there was enough support within the Fed for another interest-rate cut at the central bank’s upcoming Dec. 10 policy meeting.

    However, in the last few days, perceptions have shifted – and investors and economists now think the Fed is likely to cut.

    What sparked this turnaround? Economists say Fed officials are coalescing around another rate cut due to continued concern about the health of the jobs market.

    “The deterioration we’ve seen in the labor market, I think, is enough justification for the Fed to cut in December,” said Tom Porcelli, chief economist at Wells Fargo, in an interview.

    The first important official data released since the end of the government shutdown showed the unemployment rate rose to 4.4% in September, the highest level in almost four years. And there was some indication that the “low hiring, low firing” dynamic seen in the labor market might be on the cusp of worsening.

    The jobs market remains “in a precarious spot,” said Matthew Luzzetti, chief U.S. economist at Deutsche Bank, in a note to clients.

    In an interview, Josh Hirt, senior economist at Vanguard, said it was his personal view that the Fed would cut rates. He noted how, on Friday, New York Fed President John Williams, a close ally of Fed Chair Jerome Powell, made a strong case for a rate cut and said he “stills sees room for a further adjustment in the near term.”

    This moved financial markets, as the expectations of a December rate cut rose sharply to above 70%, from near 40% the day before.

    “I think the market has the right read on it,” Hirt said.

    The Vanguard economist added that Williams’s speech meant three of the most influential Fed officials – Powell, Williams and Fed governor Christopher Waller – all support another easing move.

    “We think that’s a pretty strong group to try to overcome,” Hirt said.

    Ethan Harris, former chief economist at BofA Securities, said the economy is starting to show more convincing signs of weakening, pushing the Fed to act.

    Economists think there will be a dissent from one or more Fed officials who want to hold interest rates steady.

    The Fed has already cut rates via two successive quarter-percentage-point moves in September and October, bringing its benchmark rate down to a range of 3.75% to 4%.

    Former Cleveland Fed President Loretta Mester said that Powell could use his press conference on Dec. 10 to send a message that this cut was an insurance move and the Fed would then wait and see how the economy reacts.

    Because of the record-length government shutdown, the Fed won’t have the government’s latest job and inflation data at their meeting.

    Stepping back, the Fed is facing an impossible challenge, Harris said. They are dealing with stagflationary dynamics – higher inflation and higher job losses at the same time – which do not have an obvious Fed policy response. This has divided the rate-setting committee.

    “There are some very fundamental disagreements,” Harris said.

    The first is whether current Fed policy is tight or loose. Fed officials who are uneasy about inflation say monetary policy works through capital markets, which are doing great – a sign policy might be easy already. Officials who want to cut rates say that financial conditions in key sectors like housing are tight.

    The second disagreement is over how to interpret inflation. Officials, like Williams, who want to cut rates said inflation would be low if it wasn’t for the temporary impact of tariffs. Officials who are worried about inflation see signs it is rising in sectors not impacted by tariffs.

    On top of that, all Fed officials are puzzled by the dichotomy between the weak job market and strong consumer spending.

    “It is going to be an interesting vote,” Harris said. The decision could be made in the meeting, he added.

    Hirt at Vanguard said the speeches by Fed officials who don’t want to cut rates in December have shown the market that the Fed isn’t just “cutting for the sake of cutting,” and so the bond market won’t start to price in higher inflation expectations.

    “It limits the negative consequences” of cutting with inflation so high and the labor market not in obvious distress, Hirt added.

    -Greg Robb

    This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.

    (END) Dow Jones Newswires

    11-22-25 0700ET

    Copyright (c) 2025 Dow Jones & Company, Inc.

    Continue Reading

  • With 70s vibes in the desert: unique Sonderwunsch Cayenne

    With 70s vibes in the desert: unique Sonderwunsch Cayenne




    The Icons of Porsche event is the largest car festival in the Middle East region. Porsche fans from all over the world came to Dubai this year to admire rare Porsche sports cars in front of a spectacular backdrop and to exchange ideas with like-minded people. One of the highlights was the elaborate conversion of a Cayenne as part of the Sonderwunsch program.


    Breaking new ground is part of the Cayenne’s product philosophy. This also applies to an unusual project: for the first time, Porsche has completely overhauled and extensively individualised a first-generation Cayenne on behalf of a customer as part of the “Factory Re-Commission” Sonderwunsch category.

    The Cayenne is an icon

    “So far, we have mainly carried out such elaborate Factory Re-Commission projects for classic Porsche or for rarities such as the Carrera GT,” says Alexander Fabig, Vice President Individualisation and Classic at Porsche. “The fact that we have now rebuilt a 16-year-old Cayenne to new car condition and made it an absolutely unique piece shows how diverse the dreams of Porsche enthusiasts are. And it once again underlines the iconic status of the Cayenne.” 

    The client was Phillip Sarofim, entrepreneur and passionate car collector. The American had turned to Porsche with very specific ideas: “The look of the 911 Spirit 70 made a lasting impression and inspired me. I really wanted such 1970s vibes for my Cayenne as well.” The basis was a 2009 Cayenne GTS with around 50,000 miles, the equivalent of almost 80,500 kilometers, on the odometer. The only catch: there was none – only a towbar had to be retrofitted. Because a dream trip with the new old Porsche also took shape early on: “From the very beginning, I had the idea of driving through the Rub al-Khali Desert near Dubai,” Sarofim recalls, “with a large Airstream caravan.”

    Cayenne GTS (2009), Sonderwunsch, 2025, Porsche AG





    A towbar was retrofitted for the American cult caravan, namely the typical US “receiver system” with square mount. Coarse tyres improve traction and underline the striking look. To achieve the desired retro look, the exterior is finished in Blackolive, a Paint to Sample color. The lower part of the body as well as the alloy wheels, on the other hand, are finished in matt black, which reinforces the off-road character of the SUV.

    In the interior, the extensive leather upholstery in English green (Leather to Sample) meets the iconic Pasha pattern in black/olive. The seat centres, but also the glove compartment inside, are covered with this typical Porsche textile. Cleverly arranged rectangles of different sizes create a kind of movement in the pattern. The trim strips on the passenger side and in the doors form a noble contrast: just like the door openers and their frames, they are finished in light-brushed aluminium.

    So there’s nothing to stop you from riding into the desert any time soon – and with this Factory Re-Commission, the Cayenne has once again proven its versatility and pioneering spirit.


    About Factory Re-Commission

    If customers want high-end vehicle customization for a vehicle they already own, they will find what they are looking for at Sonderwunsch Factory Re-Commission. As part of this offer, the colours and materials in the interior and exterior can be completely reselected. After contact has been established between the customer and the Sonderwunsch team, an initial assessment of the technical feasibility for the colour and equipment request is made. A cost estimate will be prepared as soon as the vehicle has been brought to Zuffenhausen for inspection by the Sonderwunsch experts. For these reasons, this offering focuses on whole-vehicle concepts rather than retrofitting individual options. The older the customer’s vehicle, the more likely it is that technical repair work will be necessary in combination with individualization. This is especially true for classic cars, where a factory restoration is often a mandatory part of the project.

    About the first Cayenne generation

    Ferry Porsche sensed the chances of success of a Porsche SUV as early as 1989: “If we built an off-road vehicle according to our quality expectations, and Porsche was written on the front, it would also be sold.” He was right: since 2002, the Cayenne has been opening up new customer bases as a family-friendly touring vehicle that is both a robust off-roader and a highly dynamic sports car. Developed under the code name Colorado, the first generation (internally called E1) was launched in 2002. In the meantime, these models, which were produced until 2010, have a loyal fan base, and Porsche is already looking after them as youngtimers.

    Continue Reading

  • Gold price rises by Rs2,300 per tola

    Gold price rises by Rs2,300 per tola

    – Advertisement –

    – Advertisement –

    – Advertisement –

    ISLAMABAD, Nov 22 (APP): The price of 24-karat gold increased by Rs2,300 on Saturday, reaching Rs428,862 per tola, compared to Rs426,562 on the previous day, according to the All Pakistan Sarafa Gems and Jewellers Association.
    Similarly, the price of 10 grams of 24-karat gold rose by Rs1,972, climbing to Rs367,680 from Rs365,708 a day earlier. The 10 grams of 22-karat gold were sold for Rs337,052, up by Rs1,808, against the previous rate of Rs335,244.
    In the international market, gold prices increased by $23, reaching $4,065 compared to $4,042 on the preceding day.
    Likewise, the per tola price of 24-karat silver surged by Rs48, settling at Rs5,270 against Rs5,222 on Friday. The price of 10 grams of 24-karat silver rose to Rs4,518, marking an increase of Rs41 from Rs4,477 previously.
    International silver was traded at $49.98, showing a rise of $0.48 compared to $49.50 on the last trading day.

    Continue Reading